PharmaForce Appoints Industry Leader Lynn Eschenbacher to Lead Next Phase of 340B Strategy and Execution

Audio By Carbonatix

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Apr 7, 2026--

PharmaForce, a leader in modern 340B program management, today announced the appointment of Lynn Eschenbacher, PharmD, MBA, FASHP, as Chief Pharmacy and Strategy Officer, reinforcing its commitment to delivering enterprise-grade performance, operational discipline, and a forward-looking strategy for the evolving 340B landscape.

Dr. Eschenbacher joins PharmaForce with more than 25 years of pharmacy leadership experience spanning health systems, pharmacy operations, and enterprise strategy. Most recently, she served as Chief Pharmacy and Strategy Officer at Quva Pharma. Prior to that, she held senior leadership roles, including Chief Pharmacy Officer at Ascension, along with earlier positions at WakeMed Health & Hospitals and Duke University Hospital.

Her appointment comes at a pivotal moment for 340B, one that is redefining what health systems require from their partners.

Across the market, 340B execution is becoming more complex, and the margin for error is shrinking. Health systems are navigating increasing regulatory scrutiny, evolving manufacturer dynamics, and rising expectations for both compliance and financial performance. At the same time, many organizations remain constrained by fragmented systems, delayed reporting, and manual workflows that limit visibility and slow decision-making.

The conversation is shifting from growth to operational precision.

Health systems now expect enterprise-grade stability and scalability, AI-driven oversight and real-time insight, disciplined, repeatable implementations, and a partner with a clear point of view on where 340B is headed.

This shift is not only necessary; it’s healthy for the industry. And it’s where PharmaForce is focused.

“340B has become a critical lever for health systems, but the expectations around execution have fundamentally changed,” said Rob Kill, CEO of PharmaForce. “This is no longer about retrospective reporting; it’s about real-time control, predictive insight, and operational discipline at scale. Lynn brings the exact combination of clinical credibility and enterprise leadership needed to help our clients meet that moment.”

At PharmaForce, Dr. Eschenbacher will lead pharmacy strategy, clinical alignment, and industry engagement. She will work closely with clients to strengthen oversight across contract pharmacy, improve program performance, and navigate evolving policy and market dynamics with greater precision and confidence.

She will also play a key role in advancing PharmaForce’s AI-driven strategy, helping health systems move from reactive program management to proactive, insight-led execution.

PharmaForce’s platform is purpose-built for enterprise readiness, enabling connected data, real-time visibility, and disciplined workflows across the 340B ecosystem. By replacing fragmented tools and manual processes with a unified, intelligent system, PharmaForce empowers organizations to operate with greater clarity, control, and consistency.

“Health systems don’t need more complexity. They need the ability to deliver, with precision, on the promise 340B makes to patients,” said Dr. Eschenbacher. “As these programs grow more complex, legacy approaches are no longer enough. We’re taking a fundamentally different path by combining AI-driven insight, enterprise discipline, and deep operational expertise to ensure savings are not just generated, but reliably converted into care for the people who depend on them.”

As 340B continues to evolve, PharmaForce is helping define what comes next: A more disciplined, transparent, technology-enabled model operationalized with precision, accountability, and consistency across the enterprise.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260407711757/en/

CONTACT: Media Contact:

Hilary Cull

[email protected]

KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH TECHNOLOGY HOSPITALS PRACTICE MANAGEMENT HEALTH TECHNOLOGY ARTIFICIAL INTELLIGENCE PHARMACEUTICAL

SOURCE: PharmaForce

Copyright Business Wire 2026.

PUB: 04/07/2026 10:00 AM/DISC: 04/07/2026 10:00 AM

http://www.businesswire.com/news/home/20260407711757/en